Skip to main content

Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease

  • Conference paper
Continuous Dopaminergic Stimulation in Parkinson’s Disease

Part of the book series: Journal of Neural Transmission ((NEURAL SUPPL,volume 27))

  • 101 Accesses

Summary

The experience that the supplementation of depleted dopamine in the nigro-striatal system of parkinsonian patients with L-dopa improves the clinical triad, akinesia, rigidity and tremor, mainly applies to long-term treatment in the early phase of Parkinson’s disease. Complications in motor performance, like on-off response, wearing-off phenomena, peak-dose dyskinesia, biphasic dyskinesia, off-period dystonia and others, after more than 3 to 5 years following the onset of treatment indicate fluctuations in the dopaminergic feedback control system. It is suggested that these complications are due to progressive presynaptic degeneration and late changes in postsynaptic receptor amplification. However, as fluctuations are not imperative in all patients, an important additional aspect seems to be the topography of denervation, which involves different portions of the striatum to varying degrees. Location and extent of denervation are criteria which appear to have predictive value for the malignancy of the disease, the therapeutic response of drugs and complications in long-term treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Birkmayer W, Riederer P, Youdim MBH (1979) Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neurosurg 158: 81–83

    Google Scholar 

  • Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2nd edn. Springer, Wien New York

    Book  Google Scholar 

  • Brücke T, Danielczyk W, Simanyi M, Sofie E, Riederer P (1987) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 573–576

    Google Scholar 

  • Carlsson A (1983) Are “On-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm [Suppl] 19: 153–161

    Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. J Neural Transm 62: 171–207

    Article  PubMed  CAS  Google Scholar 

  • Corsini GU, Horowski R, Reiner E, del Zompo M (1984) Treatment of Parkinson’s disease with a dopamine partial agonist. Clin Neuropharmacol 7: 950–951

    Article  Google Scholar 

  • Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24: 1278–1282

    PubMed  CAS  Google Scholar 

  • Goldstein M, Lieberman A, Meiler E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. TIPS (Nov.) 436–437

    Google Scholar 

  • Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D 2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 487–492

    Article  Google Scholar 

  • Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429–436

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 19–34

    Google Scholar 

  • Jellinger K (1986) Overview of morphological changes in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 1–18

    Google Scholar 

  • Kapfhammer HP, Kuss HJ, Eben E, Rüther E (1985) L-dopa infusion experiments in combination with the L-dopa-decarboxylase inhibitors benserazide and carbidopa: L- dopa metabolism and neuroendocrinological effects. Pharmacopsychiat 18: 143–144

    Google Scholar 

  • Karobath M (1985) Neue Aspekte in der Pharmakotherapie des M. Parkinson. In: Schna- berth G, Auff E (eds) Das Parkinson-Syndrom. Proceedings, Symposium 1984. Wissenschaftlicher Dienst “Roche”, Basle, pp 211–216

    Google Scholar 

  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 86–122

    Google Scholar 

  • Muenter MD, Sharpless NS, Tyce GM, Darley L (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy of Parkinson’s disease. Mayo Clin Proc 52: 163–174

    PubMed  CAS  Google Scholar 

  • Poewe WH, Lees AJ, Stern GM (1986) Treatment of motor fluctuations in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9: 430–439

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seeman D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 14: 121–132

    CAS  Google Scholar 

  • Riederer P (1986) Neurobiochemische Aspekte zur Progression der Parkinson-Krankheit: Post-mortem Befunde und MPTP-Modell. In: Fischer PA (ed) Spätsyndrome der Parkinson-Krankheit. Proceedings, Parkinson-Symposium 1986, Frankfurt. Wissenschaftlicher Dienst “Roche”, Basle, pp 37–48

    Google Scholar 

  • Rinne UK (1986) The importance of an early combination of a dopamine agonist and levodopa in the treatment of Parkinson’s disease. In: Van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Proceedings of a symposium, Berlin 1985. Excerpta Medica, Amsterdam, pp 64–71

    Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313

    PubMed  CAS  Google Scholar 

  • Seeman P, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology, in press

    Google Scholar 

  • Wesemann W (1984) Aspekte zum Wirkmechanismus von Amantadin. In: Danielczyk W, Wesemann W (eds) Amantadin-Workshop. Edition Materia Medica, Socio-Medico Verlag, Gräfelfing

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag

About this paper

Cite this paper

Riederer, P. (1988). Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson’s disease. In: Obeso, J.A., Horowski, R., Marsden, C.D. (eds) Continuous Dopaminergic Stimulation in Parkinson’s Disease. Journal of Neural Transmission, vol 27. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8954-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-8954-2_16

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82034-6

  • Online ISBN: 978-3-7091-8954-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics